Endovascular AAA Intervention Using the GORE® EXCLUDER® Conformable AAA Endoprosthesis or Iliac Branch Endoprosthesis

Description

A prospective, observational post-market registry collecting outcomes through a 10-year post procedure follow-up for patients treated with the GORE® EXCLUDER® Conformable AAA Endoprosthesis (EXCC Device) or the GORE® EXCLUDER® Iliac Branch Endoprosthesis (IBE Device) as a part of routine clinical practice.

Conditions

AAA - Abdominal Aortic Aneurysm

Talk to us

Study Overview

On this page

Study Details

Study overview

A prospective, observational post-market registry collecting outcomes through a 10-year post procedure follow-up for patients treated with the GORE® EXCLUDER® Conformable AAA Endoprosthesis (EXCC Device) or the GORE® EXCLUDER® Iliac Branch Endoprosthesis (IBE Device) as a part of routine clinical practice.

Assessment of Long Term, Endovascular AAA Intervention Using the GORE® EXCLUDER® Conformable AAA Endoprosthesis or Iliac Branch Endoprosthesis

Endovascular AAA Intervention Using the GORE® EXCLUDER® Conformable AAA Endoprosthesis or Iliac Branch Endoprosthesis

Condition
AAA - Abdominal Aortic Aneurysm
Intervention / Treatment

-

Contacts and Locations

Indianapolis

St. Vincent Medical Group, Inc., Indianapolis, Indiana, United States, 46260

Bay City

McLaren Heatlh Care Corporation, Bay City, Michigan, United States, 48708

Asheville

Mission Hospital, Asheville, North Carolina, United States, 28801

Plano

Columbia Medical Center of Plano, Plano, Texas, United States, 75075

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Patient or legally authorized representative (LAR) provides written authorization and/or consent per institution and geographical requirements
  • 2. Patient has been or is intended to be treated with an eligible registry device
  • 3. Patient is age ≥ 18 years at time of informed consent signature.
  • 1. Patient who is, at the time of consent, unlikely to be available for standard of care (SOC) follow-up visits as defined by the site's guidelines and procedures.
  • 2. Patient with exclusion criteria required by local law.
  • 3. Patient is currently enrolled in or plans to enroll in any concurrent drug and/or device study within 12 months of Together Registry enrollment. Subjects cannot be enrolled in another Together Registry module protocol.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

W.L.Gore & Associates,

S. Han, PRINCIPAL_INVESTIGATOR, University of Southern California

Study Record Dates

2042-09-30